Compoundeer Logo
COMPOUNDEER
Uncovering Potential
RankingCompaniesDCF
LLY Logo

Eli Lilly & Co

LLY

Pharmaceutical Preparations

Mkt Cap

$532.4B

PE

106.73

Debt

$20.17B

Cash

$2.381B

EV

$550.2B

FCF

$3.254B

Market Cap

$532.4B

P/E Ratio

106.73

Debt

$20.17B

Cash

$2.381B

EV

$550.2B

FCF

$3.254B

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Sector

  • ABBV Logo

    ABBV

  • ABCL Logo

    ABCL

  • ABT Logo

    ABT

  • ABUS Logo

    ABUS

  • AGIO Logo

    AGIO

  • AKRO Logo

    AKRO

  • ALKS Logo

    ALKS

  • ALNY Logo

    ALNY

  • ALPN Logo

    ALPN

  • AMLX Logo

    AMLX

  • AMPH Logo

    AMPH

  • AMRN Logo

    AMRN

  • AMRX Logo

    AMRX

  • ANAB Logo

    ANAB

  • ANIP Logo

    ANIP

  • APLS Logo

    APLS

  • ARDX Logo

    ARDX

  • ARVN Logo

    ARVN

  • ARWR Logo

    ARWR

  • AUPH Logo

    AUPH

  • AVDL Logo

    AVDL

  • AVTE Logo

    AVTE

  • AXSM Logo

    AXSM

  • BBIO Logo

    BBIO

  • BCYC Logo

    BCYC

  • BGNE Logo

    BGNE

  • BHVN Logo

    BHVN

  • BMEA Logo

    BMEA

  • BMRN Logo

    BMRN

  • BMY Logo

    BMY

  • BPMC Logo

    BPMC

  • CBAY Logo

    CBAY

  • CDMO Logo

    CDMO

  • CERE Logo

    CERE

  • CNTA Logo

    CNTA

  • COGT Logo

    COGT

  • COLL Logo

    COLL

  • CORT Logo

    CORT

  • CPRX Logo

    CPRX

  • CRNX Logo

    CRNX

  • CTLT Logo

    CTLT

  • CYRX Logo

    CYRX

  • CYTK Logo

    CYTK

  • DAWN Logo

    DAWN

  • DCPH Logo

    DCPH

  • DVAX Logo

    DVAX

  • DYN Logo

    DYN

  • ELAN Logo

    ELAN

  • EOLS Logo

    EOLS

  • EQRX Logo

    EQRX

  • ETNB Logo

    ETNB

  • EWTX Logo

    EWTX

  • FOLD Logo

    FOLD

  • GERN Logo

    GERN

  • HRMY Logo

    HRMY

  • HZNP Logo

    HZNP

  • ICPT Logo

    ICPT

  • IDYA Logo

    IDYA

  • IMGN Logo

    IMGN

  • INSM Logo

    INSM

  • INVA Logo

    INVA

  • IONS Logo

    IONS

  • IRON Logo

    IRON

  • IRWD Logo

    IRWD

  • ITCI Logo

    ITCI

  • JANX Logo

    JANX

  • JAZZ Logo

    JAZZ

  • JNJ Logo

    JNJ

  • KNSA Logo

    KNSA

  • KROS Logo

    KROS

  • KRTX Logo

    KRTX

  • KURA Logo

    KURA

  • LFCR Logo

    LFCR

  • LGND Logo

    LGND

  • LQDA Logo

    LQDA

  • LYEL Logo

    LYEL

  • MDGL Logo

    MDGL

  • ME Logo

    ME

  • MGNX Logo

    MGNX

  • MIRM Logo

    MIRM

  • MLTX Logo

    MLTX

  • MNKD Logo

    MNKD

  • MORF Logo

    MORF

  • MRK Logo

    MRK

  • MRNS Logo

    MRNS

  • MRTX Logo

    MRTX

  • MRUS Logo

    MRUS

  • MRVI Logo

    MRVI

  • NATR Logo

    NATR

  • NRIX Logo

    NRIX

  • OGN Logo

    OGN

  • OLMA Logo

    OLMA

  • OPK Logo

    OPK

  • ORGO Logo

    ORGO

  • ORIC Logo

    ORIC

  • PAHC Logo

    PAHC

  • PBAJ Logo

    PBAJ

  • PBH Logo

    PBH

  • PCRX Logo

    PCRX

  • PFE Logo

    PFE

  • PHAT Logo

    PHAT

  • PLRX Logo

    PLRX

  • PNT Logo

    PNT

  • PRGO Logo

    PRGO

  • PRTA Logo

    PRTA

  • PTCT Logo

    PTCT

  • PTGX Logo

    PTGX

  • QURE Logo

    QURE

Growth

%

%

Discount

%

%

Multiple

g\r+10%+11%+12%+13%+14%
0%109887
+1%1110988
+2%13111098
+3%141311109
+4%1714121110
Years012345678910TV
FCF$3.254B$3.495B$3.745B$4.003B$4.268B$4.539B$4.814B$5.094B$5.376B$5.659B$5.942B$59.42B
DCF$3.04B$2.832B$2.632B$2.44B$2.257B$2.081B$1.915B$1.757B$1.609B$1.469B$14.69B
Value$36.72B

In the chart Earnings are multiplied by this value.

Earnings Growth 17%
Earnings Stability 44%


Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12-201412-201512-201612-201712-201812-201912-202012-202112-2022TTM
Net Margin12%12%13%-0.89%13%37%25%20%22%16%
ROA8.5%7.8%8.7%4.9%8.6%13%16%13%14%11%
ROE16%17%19%-1.7%30%310%110%61%58%44%

What is the average Net Margin?

The average Net Margin over the past 5 years is +19.39%.

What is the trend of Net Margin?

The trend of Net Margin over the past 5 years is +3.47%.

What is the average Return on Assets (ROA)?

The average ROA over the past 5 years is +11.47%.

What is the trend of Return on Assets (ROA)?

The trend of ROA over the past 5 years is +1.67%.

What is the average Return on Equity (ROE)?

The average ROE over the past 5 years is +93.55%.

What is the trend of Return on Equity (ROE)?

The trend of ROE over the past 5 years is +5.45%.


Safety & Stabiliy

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12-201412-201512-201612-201712-201812-201912-202012-202112-2022TTM
Debt FCF2.514.682.873.012.964.033.253.073.126.20
Debt Equity0.520.550.781.171.175.672.852.001.511.78
MIN
Graham Stability--87%-8.1%100%100%100%94%93%-8.1%

What is the Debt/FCF?

The Debt/FCF trailing twelve month is 6.20.

What is the trend of Debt/FCF?

The trend of Debt/FCF over the past 5 years is 0.00.

What is the Graham’s Stability?

Graham’s Stability measure stands at -0.08.


Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12-201512-201712-201912-2021Trend
Revenue5.2%4.5%8.5%0.79%1.6%
Net Income15%--9.1%12%4.7%
Stockholders Equity-4.2%-1.6%59%18%8.2%
FCF17%2.9%11%-12%1%

What is the 5 year Revenue CAGR?

The Revenue CAGR over the past 5 years is +4.53%.

What is the trend of Revenue growth?

The trend of Revenue growth rate over the past 5 years is +1.58%.

What is the 5 year Earnings CAGR?

The Earnings CAGR over the past 5 years is -.

What is the trend of Earnings growth?

The trend of Earnings growth rate over the past 5 years is +4.69%.

What is the 5 year Equity CAGR?

The Equity CAGR over the past 5 years is -1.58%.

What is the trend of Equity growth?

The trend of Equity growth rate over the past 5 years is +8.16%.

What is the 5 year FCF CAGR?

The FCF CAGR over the past 5 years is +2.88%.

What is the trend of FCF growth?

The trend of FCF growth rate over the past 5 years is +1.01%.